Want to see DSGN full AI Analyst Report?
Design Therapeutics (DSGN) Stock Statistics & Valuation Metrics
Total Valuation
Design Therapeutics has a market cap or net worth of $668.37M. The enterprise value is $699.72M.
- Market Cap
- $668.37M
- Enterprise Value
- $699.72M
Share Statistics
Design Therapeutics has 62,581,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 62,581,650
- Owned by Insiders
- 10.98%
- Owned by Institutions
- 17.00%
Financial Efficiency
Design Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.13%.
- Return on Equity (ROE)
- -0.33
- Return on Assets (ROA)
- -0.31
- Return on Invested Capital (ROIC)
- -37.13%
- Return on Capital Employed (ROCE)
- -0.37
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.27M
- Employee Count
- 55
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Design Therapeutics is -9.05. Design Therapeutics’s PEG ratio is 1.63.
- PE Ratio
- -9.05
- PS Ratio
- 0.00
- PB Ratio
- 3.31
- Price to FCF
- -12.12
- Price to Operating Cash Flow
- -12.12
- PEG Ratio
- 1.63
Income Statement
In the last 12 months, Design Therapeutics had revenue of 0 and earned -69.79M in profits. Earnings per share was -1.22.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -79.47M
- Pretax Income
- -69.79M
- Net Income
- -69.79M
- EBITDA
- -69.17M
- Earnings Per Share (EPS)
- -1.22
Cash Flow
In the last 12 months, operating cash flow was -55.08M and capital expenditures -55,000, giving a free cash flow of -55.14M billion.
- Operating Cash Flow
- -55.08M
- Free Cash Flow
- -55.14M
- Free Cash Flow per Share
- -0.88
Dividends & Yields
Design Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.25%
- Earnings Yield
- -10.61%
Stock Price Statistics
- Beta
- 1.09
- 52-Week Price Change
- 63.55%
- 50-Day Moving Average
- 12.74
- 200-Day Moving Average
- 12.23
- Relative Strength Index (RSI)
- 42.42
- Average Volume (3m)
- 585.10K
Important Dates
Design Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Design Therapeutics as a current ratio of 17.14, with Debt / Equity ratio of 0.72%
- Current Ratio
- 17.14
- Quick Ratio
- 17.14
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.22
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Design Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Design Therapeutics EV to EBITDA ratio is -9.11, with an EV/FCF ratio of -11.92.
- EV to Sales
- 0.00
- EV to EBITDA
- -9.11
- EV to Free Cash Flow
- -11.92
- EV to Operating Cash Flow
- -11.94
Balance Sheet
Design Therapeutics has $207.40M in cash and marketable securities with $2.03M in debt, giving a net cash position of $205.37M billion.
- Cash & Marketable Securities
- $207.40M
- Total Debt
- $2.03M
- Net Cash
- $205.37M
- Net Cash Per Share
- $3.28
- Tangible Book Value Per Share
- $3.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Design Therapeutics is $26.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $26.11
- Price Target Upside
- 144.46% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -5.51%
Scores
- Smart Score
- 5
- AI Score
- 52